glp-1 chronic fatigue syndrome Glucagon-like peptide-1 receptor agonists and muscle mass effects This One Mistake Puts GLP-1

Bruscolini A, Sacchetti M, La Cava M, Nebbioso M, Iannitelli A, Quartini A et al (2018) Quality of life and neuropsychiatric disorders in patients with graves orbitopathy: current concepts

Claims brought in the MDL include failure to warn, design defect, and breach of warranty allegations against the drug manufacturers

Broad impact of oxidative stress Oxidative stress is a central driver of PD pathology

However, long-term pramlintide treatment is limited by low bioavailability and the short half-life of the drug, which makes it less suitable for chronic therapy due to the high administration frequency (two to three times daily) and therefore high compliance-related demands